arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

Tvardi Therapeutics, Inc.

TVRD Health Care Biotechnology: Pharmaceutical Preparations
$0.97
▼ -2.0% Today
as of Oct 22, 16:53 ET
Last 30 days -46.89% Sep 14 → Oct 22
$0.90 $1.15 $1.40 $1.65 $1.90 Sep 14 Sep 22 Sep 29 Oct 07 Oct 14 Oct 22
Open
$1.01
High
$1.05
Low
$0.97
Volume
$54,431
Avg Vol
$670,084
Mkt Cap
$17M
P/E (TTM)
—
Beta
—
52w High
$5.69
52w Low
$0.93
Div Yield
—
Shares Out
$9M

Recent Press Releases & News last 60 days · 4 items

Oct 20 · 10:54 MT Newswires
Chardan Initiates Tvardi Therapeutics at Buy With $8 Price Target
Oct 14 · 12:00 PR GlobeNewswire
Tvardi Therapeutics to Participate in Chardan’s 10th Annual Healthcare Conference
Sep 24 · 12:00 PR GlobeNewswire
New Preclinical Data Further Support Potential for Tvardi’s STAT3 Inhibitors in Ulcerative Colitis (UC)
▸ Show all 4 press releases & news Free account →

TVRD earnings at a glance

The options market is pricing a move of about ±203.7% after the report, a range of roughly -$1.01 to $2.95 from today's $0.97. Over its last 2 reports the stock rose the next day 1 time and fell 1, moving ±1.4% on average; after the most recent report on May 8, 2026 it moved -0.7%. That means options currently expect more movement than TVRD has typically delivered. TVRD beat the consensus EPS estimate in 1 of its last 3 reported quarters. Implied volatility is currently 17%. The share price of $0.97 sits near its 52-week low.

More Health Care stocks · All stocks · Earnings calendar

Overview

52-week range
$0.93
$5.69
1% of range
Avg surprise (last 3)
-26.5%
Avg reaction (last 2)
+0.7%
50% positive
Latest IV / EM
1724%
EM ±203.7% · $3 · Oct 16

Earnings trends

EPS — actual vs estimate Actual Estimate
$-20.24$-14.93$-9.62$-4.31$1.00 Actual $-0.49Actual $-0.58Actual $-0.52Actual $-20.24Actual $-2.71Actual $-2.14Actual $-3.22Actual $1.00Est $-0.51Actual $-0.59Est $-0.83Actual $-0.73Est $-0.65Actual $-0.69 MarJunSepMarJunSepMar/2025Jun/2025Sep/2025Mar/2026Jun
Revenue vs Net Income Revenue Net income
$-10M$-6M$-3M$886,762$4M Sep 24Mar 25Jun 25Sep 25Mar 26Jun 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Tue Jun 30, 2026Jun 2026 $-0.69 — — — — financials
Fri May 8, 2026Mar/2026 $-0.73 $-0.65 -12.3% +77.3% -0.7% earnings
Thu Nov 13, 2025Sep/2025 $-0.59 $-0.83 +28.9% — — earnings
Thu Aug 14, 2025Jun/2025 $1.00 $-0.51 -96.1% — — earnings
Tue May 13, 2025Mar/2025 $-3.22 — — — +2.1% earnings
Mon Sep 30, 2024Sep 2024 $-2.14 — — — — financials
Sun Jun 30, 2024Jun 2024 $-2.71 — — — — financials
Sun Mar 31, 2024Mar 2024 $-20.24 — — — — financials
Sat Sep 30, 2023Sep 2023 $-0.52 — — — — financials
Fri Jun 30, 2023Jun 2023 $-0.58 — — — — financials
Fri Mar 31, 2023Mar 2023 $-0.49 — — — — financials

Financials

Income statement (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue—————$3M—$3M
Cost of revenue————————
Gross profit————————
Operating income$-7M$-7M—$-6M$-9M$-4M—$-6M
Net income$-6M$-7M—$-6M$4M$-10M—$-6M
EPS (diluted)$-0.69$-0.73—$-0.59$-1.00$-3.72—$-2.14

Balance sheet (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Cash & equivalents$16M$20M$21M$21M$21M$34M$32M$37M
Inventory—————$900,000$900,000$625,000
Total current assets$17M$25M$32M$38M$43M—$32M$48M
Total assets$18M$26M$32M$39M$44M$39M$35M$51M
Long-term debt————————
Total liabilities$9M$11M$11M$11M$11M$47M$41M$51M
Total equity$8M$15M$21M$28M$33M$-101M$-91M$-79M

Implied volatility — last 90 days

141%1898%3655%5411%7168% Jun 16 — IV 161% · EM ±9.5%Jun 17 — IV 186% · EM ±7.8%Jun 19 — IV 869% · EM ±192.0%Jun 22 — IV 902% · EM ±188.4%Jun 23 — IV 980% · EM ±200.4%Jun 24 — IV 1073% · EM ±214.9%Jun 25 — IV 1092% · EM ±214.0%Jun 26 — IV 1571% · EM ±300.6%Jun 29 — IV 1484% · EM ±263.0%Jun 30 — IV 1603% · EM ±276.0%Jul 01 — IV 1550% · EM ±259.0%Jul 02 — IV 1431% · EM ±231.5%Jul 03 — IV 1489% · EM ±232.7%Jul 06 — IV 1814% · EM ±251.2%Jul 07 — IV 269% · EM ±35.5%Jul 08 — IV 965% · EM ±121.0%Jul 09 — IV 355% · EM ±41.9%Jul 10 — IV 453% · EM ±50.0%Jul 13 — IV 635% · EM ±53.0%Jul 14 — IV 495% · EM ±35.8%Jul 15 — IV 391% · EM ±23.1%Jul 16 — IV 599% · EM ±25.0%Jul 20 — IV 148% · EM ±35.0%Jul 21 — IV 142% · EM ±32.9%Jul 22 — IV 177% · EM ±40.6%Jul 23 — IV 174% · EM ±39.1%Jul 24 — IV 151% · EM ±33.3%Jul 27 — IV 193% · EM ±40.4%Jul 28 — IV 972% · EM ±198.8%Jul 29 — IV 992% · EM ±198.8%Jul 31 — IV 746% · EM ±142.9%Aug 03 — IV 1187% · EM ±210.4%Aug 04 — IV 1164% · EM ±200.5%Aug 05 — IV 419% · EM ±70.0%Aug 06 — IV 1307% · EM ±211.4%Aug 07 — IV 633% · EM ±98.9%Aug 10 — IV 635% · EM ±88.0%Aug 11 — IV 1830% · EM ±241.7%Aug 12 — IV 1871% · EM ±234.5%Aug 13 — IV 1985% · EM ±234.5%Aug 14 — IV 417% · EM ±46.1%Aug 17 — IV 901% · EM ±75.3%Aug 18 — IV 3399% · EM ±245.8%Aug 19 — IV 1086% · EM ±64.2%Aug 20 — IV 5561% · EM ±232.2%Aug 24 — IV 363% · EM ±75.8%Aug 25 — IV 336% · EM ±68.7%Aug 26 — IV 393% · EM ±78.7%Aug 27 — IV 255% · EM ±50.0%Aug 28 — IV 359% · EM ±68.7%Aug 31 — IV 394% · EM ±69.8%Sep 01 — IV 1581% · EM ±272.2%Sep 02 — IV 1553% · EM ±259.4%Sep 03 — IV 1671% · EM ±270.3%Sep 04 — IV 1625% · EM ±253.9%Sep 07 — IV 1833% · EM ±253.9%Sep 08 — IV 1844% · EM ±243.6%Sep 09 — IV 1014% · EM ±127.0%Sep 10 — IV 2307% · EM ±272.5%Sep 11 — IV 895% · EM ±98.9%Sep 14 — IV 3173% · EM ±265.0%Sep 15 — IV 1586% · EM ±114.7%Sep 16 — IV 4980% · EM ±294.1%Sep 17 — IV 7169% · EM ±299.4%Sep 21 — IV 610% · EM ±127.3%Sep 22 — IV 1598% · EM ±326.9%Sep 23 — IV 1694% · EM ±339.3%Sep 24 — IV 2288% · EM ±448.1%Sep 25 — IV 746% · EM ±142.9%Sep 28 — IV 2100% · EM ±372.2%Sep 29 — IV 2291% · EM ±394.5%Sep 30 — IV 2323% · EM ±388.0%Oct 01 — IV 2418% · EM ±391.1%Oct 02 — IV 2707% · EM ±423.1%Oct 05 — IV 2859% · EM ±396.0%Oct 06 — IV 3470% · EM ±458.3%Oct 07 — IV 3664% · EM ±459.1%Oct 08 — IV 1724% · EM ±203.7%

Sector peers

ALLR
Allarity Therapeutics, Inc.
$17M $0.85-3.4%
DARE
Dare Bioscience, Inc.
$17M $0.65-5.4%
RKTO
Rocket One Inc.
$17M $0.53+0.3%
LPCN
Lipocine Inc.
$18M $1.46-9.9%
CYCN
Cyclerion Therapeutics, Inc.
$18M $3.36-85.7%
KPTI
Karyopharm Therapeutics Inc.
$15M $0.55+52.1%

TVRD earnings FAQ

What is TVRD's expected move for earnings?

Options currently price a move of about ±203.7%, or $1.98 per share either way from $0.97.

How does TVRD stock usually react to earnings?

Across the last 2 reports the average next-day move was ±1.4%, up 1 times and down 1 times.

What is TVRD's implied volatility?

TVRD's at-the-money implied volatility is about 17% based on the latest options snapshot.

View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in